Ignite Creation Date:
2024-05-06 @ 4:03 AM
Last Modification Date:
2024-10-26 @ 11:43 AM
Study NCT ID:
NCT02446717
Status:
COMPLETED
Last Update Posted:
2017-09-15
First Post:
2015-05-14
Brief Title:
A Study to Evaluate the Efficacy Safety and Pharmacokinetics of ABT-493 and ABT-530 With and Without Ribavirin in Adults With HCV Who Failed a Prior DAA Containing Therapy
Sponsor:
AbbVie
Organization:
AbbVie
Study Overview
Official Title:
A Randomized Open-Label Multicenter Study to Evaluate the Efficacy Safety and Pharmacokinetics of Co-Administration of ABT-493 and ABT-530 or ABT-493ABT-530 With and Without Ribavirin in Adults With Chronic Hepatitis C Virus HCV Infection Who Failed a Prior Direct-Acting Antiviral Agent DAA-Containing Therapy
Status:
COMPLETED
Status Verified Date:
2017-08
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
The purpose of this study is to assess the efficacy and safety of ABT-493 and ABT-530 with or without ribavirin RBV in participants with chronic hepatitis C virus HCV-infection who previously failed treatment with a direct acting antiviral DAA-containing regimen
Detailed Description:
None
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None
Secondary IDs
| Secondary ID | Type | Domain | Link |
|---|---|---|---|
| 2015-002350-13 | EUDRACT_NUMBER | None | None |